These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34648119)

  • 21. The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan.
    Malagola M; Iurlo A; Bucelli C; Abruzzese E; Bonifacio M; Stagno F; Binotto G; D'Adda M; Lunghi M; Crugnola M; Ferrari ML; Lunghi F; Castagnetti F; Rosti G; Lemoli RM; Sancetta R; Coppi MR; Corsetti MT; De Gobbi M; Romano A; Tiribelli M; Russo Rossi A; Russo S; Defina M; Farina M; Bernardi S; Butturini G; Pellizzeri S; Roccaro AM; Russo D
    Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):323-331. PubMed ID: 38369436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effects of Tyrosine Kinase Inhibitors (TKIs) in Monotherapy and with Add-on Treatments on Health-related Quality of Life of People with Chronic Myeloid Leukemia: A Systematic Review of Randomized-Controlled Trials.
    Nardi AE; Sancassiani F; Barrui V; Kalcev G; Uras V; Meloni G; Marongiu L; Tamburini G; Maleci A; Quagliato LA; La Nasa G; Carta MG
    Clin Pract Epidemiol Ment Health; 2023; 19(Suppl-1):e1745017921112200. PubMed ID: 38659630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health state utility and quality of life measures in patients with chronic myeloid leukemia in France.
    S F; P CM; A GB; M D; R K; P TB; J B
    Qual Life Res; 2021 Jul; 30(7):2021-2032. PubMed ID: 33651280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.
    Jiang Q; Wang H; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2619-2630. PubMed ID: 28894944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All?
    Garcia-Horton A; Lipton JH
    J Natl Compr Canc Netw; 2020 Oct; 18(10):1421-1428. PubMed ID: 33022650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.
    Breccia M; Foà R
    Curr Oncol Rep; 2018 Mar; 20(3):23. PubMed ID: 29511948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
    Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
    Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
    [No Abstract]   [Full Text] [Related]  

  • 28. Patient perceptions of treatment-free remission in chronic myeloid leukemia.
    Villemagne Sanchez LA; O'Callaghan C; Gough K; Hall K; Kashima Y; Seymour JF; Schofield P; Ross DM
    Leuk Lymphoma; 2018 Feb; 59(2):406-415. PubMed ID: 28617066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
    Caldemeyer L; Akard LP
    Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
    Iino M; Yamamoto T; Sakamoto Y
    Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of symptom burden on patient quality of life in chronic myeloid leukemia.
    Cella D; Nowinski CJ; Frankfurt O
    Oncology; 2014; 87(3):133-47. PubMed ID: 25012261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health-related quality of life using EQ-5D among chronic myeloid leukaemia patients in health centres in Klang Valley, Malaysia.
    Wan Puteh SE; Aizuddin AN; Tumian NR; Sathar J; Mohamad Selamat E
    PLoS One; 2021; 16(8):e0256804. PubMed ID: 34449814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia.
    Elsayed AG; Srivastava R; Jamil MO
    Curr Oncol Rep; 2017 Oct; 19(12):77. PubMed ID: 28988389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Tyrosine kinase inhibitor therapy discontinuation for chronic myelogenous leukemia to achieve clinical cure: current status and future perspectives].
    Kumagai T
    Rinsho Ketsueki; 2018; 59(10):2094-2103. PubMed ID: 30305514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation.
    Narra RK; Flynn KE; Atallah E
    Curr Hematol Malig Rep; 2017 Oct; 12(5):415-423. PubMed ID: 28944397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors.
    Efficace F; Cannella L
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):170-179. PubMed ID: 27913477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective.
    Saglio G; Sharf G; Almeida A; Bogdanovic A; Bombaci F; Čugurović J; Deekes N; Garcia-Gutiérrez V; de Jong J; Narbutas Š; Westerweel P; Zackova D
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):375-379. PubMed ID: 29753691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017.
    Khoury HJ; Williams LA; Atallah E; Hehlmann R
    Am Soc Clin Oncol Educ Book; 2017; 37():468-479. PubMed ID: 28561719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current perspectives for the treatment of chronic myeloid leukemia.
    Aladağ E; Haznedaroğlu İC
    Turk J Med Sci; 2019 Feb; 49(1):1-10. PubMed ID: 30761815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.
    Jiang Q; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2018 Apr; 144(4):735-741. PubMed ID: 29380058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.